Frontier Capital Management’s BridgeBio Pharma BBIO Stock Holding History

Frontier Capital Management’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$102M	Buy	1,373,057 +415,068	+43%	+$29.1M	0.95%	15
2026 Q1	$71.1M	Buy	957,989 +131,858	+16%	+$9.56M	0.73%	28
2025 Q4	$63.2M	Buy	826,131 +166,498	+25%	+$10.9M	0.67%	30
2025 Q3	$34.3M	Buy	659,633 +123,870	+23%	+$6.04M	0.31%	117
2025 Q2	$23.1M	Sell	535,763 -233,538	-30%	-$8.49M	0.21%	170
2025 Q1	$26.6M	Sell	769,301 -306,557	-28%	-$10.3M	0.29%	133
2024 Q4	$29.5M	Buy	1,075,858 +572,696	+114%	+$14.8M	0.28%	138
2024 Q3	$12.8M	Buy	503,162 +354,794	+239%	+$9.31M	0.12%	202
2024 Q2	$3.76M	Sell	148,368 -301,168	-67%	-$8.23M	0.04%	259
2024 Q1	$13.9M	Buy	+449,536	New	+$15.3M	0.13%	196

Other funds holding BBIO

Jupiter Topco New York $245B AUM

KKRC

Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

ACM

Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Frontier Capital Management's BBIO Position: Q2 2026 in Review

Frontier Capital Management increased its BridgeBio Pharma (BBIO) stake by 43% in Q2 2026, buying an estimated $29.1M and bringing the position to 1,373,057 shares worth $102M. The position accounts for 0.95% of the portfolio, ranked #15.

Frontier Capital Management first reported a position in BBIO in Q1 2024 and has held it in 10 quarters since. 474 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

Frontier Capital Management held 1,373,057 shares of BridgeBio Pharma worth $102M as of Q2 2026.
Frontier Capital Management bought 415,068 BridgeBio Pharma shares in Q2 2026, an estimated $29.1M.
BridgeBio Pharma made up 0.95% of Frontier Capital Management's portfolio in Q2 2026, its #15 holding.
Frontier Capital Management first reported a position in BridgeBio Pharma in Q1 2024 and has held it in 10 quarters since.
474 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Frontier Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.